中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2009年
1期
75-78
,共4页
奥沙利铂%胃肿瘤%化学疗法
奧沙利鉑%胃腫瘤%化學療法
오사리박%위종류%화학요법
Oxaliplatin%Stomach neoplasms%Chemotherapy
目的 观察奥沙利铂联合ELF(足叶乙甙+亚叶酸钙+5-氟尿嘧啶)方案治疗进展期胃癌的临床疗效和安全性.方法 奥沙利铂100 mg/m2,静滴2 h,第1天;亚叶酸钙200 mg/m2,静滴30 min,第1～3天;5-氟尿嘧啶500 mg/m2,静滴2 h,第1～3天;足叶乙甙100 mg/m2,静滴3 h,第1～3天;每21 d重复.治疗2个周期后,评价疗效和不良反应.结果 入组的69例患者均经病理学确诊,其中胃腺癌57例,胃印戒细胞癌12例.42例为新诊断的患者,27例患者既往曾经接受过化疗.在可评价疗效的62例患者中,完全缓解(CR)7例,部分缓解(PR)25例,总缓解率为51.6%.中位疾病进展时间为5.7个月,中位生存时间为9.2个月.主要的血液学不良反应为贫血(29.0%)、白细胞减少(51.2%)和血小板减少(21.2%),无4～5度的血液学不良反应.最常见的非血液学不良反应有恶心(46.5%)、呕吐(41.1%)、外周感觉神经毒性(47.1%)以及2度脱发(27.3%).结论 奥沙利铂联合ELF方案治疗进展期胃癌疗效确切,不良反应发生率低,是值得推广验证的新联合化疗方案.
目的 觀察奧沙利鉑聯閤ELF(足葉乙甙+亞葉痠鈣+5-氟尿嘧啶)方案治療進展期胃癌的臨床療效和安全性.方法 奧沙利鉑100 mg/m2,靜滴2 h,第1天;亞葉痠鈣200 mg/m2,靜滴30 min,第1～3天;5-氟尿嘧啶500 mg/m2,靜滴2 h,第1～3天;足葉乙甙100 mg/m2,靜滴3 h,第1～3天;每21 d重複.治療2箇週期後,評價療效和不良反應.結果 入組的69例患者均經病理學確診,其中胃腺癌57例,胃印戒細胞癌12例.42例為新診斷的患者,27例患者既往曾經接受過化療.在可評價療效的62例患者中,完全緩解(CR)7例,部分緩解(PR)25例,總緩解率為51.6%.中位疾病進展時間為5.7箇月,中位生存時間為9.2箇月.主要的血液學不良反應為貧血(29.0%)、白細胞減少(51.2%)和血小闆減少(21.2%),無4～5度的血液學不良反應.最常見的非血液學不良反應有噁心(46.5%)、嘔吐(41.1%)、外週感覺神經毒性(47.1%)以及2度脫髮(27.3%).結論 奧沙利鉑聯閤ELF方案治療進展期胃癌療效確切,不良反應髮生率低,是值得推廣驗證的新聯閤化療方案.
목적 관찰오사리박연합ELF(족협을대+아협산개+5-불뇨밀정)방안치료진전기위암적림상료효화안전성.방법 오사리박100 mg/m2,정적2 h,제1천;아협산개200 mg/m2,정적30 min,제1～3천;5-불뇨밀정500 mg/m2,정적2 h,제1～3천;족협을대100 mg/m2,정적3 h,제1～3천;매21 d중복.치료2개주기후,평개료효화불량반응.결과 입조적69례환자균경병이학학진,기중위선암57례,위인계세포암12례.42례위신진단적환자,27례환자기왕증경접수과화료.재가평개료효적62례환자중,완전완해(CR)7례,부분완해(PR)25례,총완해솔위51.6%.중위질병진전시간위5.7개월,중위생존시간위9.2개월.주요적혈액학불량반응위빈혈(29.0%)、백세포감소(51.2%)화혈소판감소(21.2%),무4～5도적혈액학불량반응.최상견적비혈액학불량반응유악심(46.5%)、구토(41.1%)、외주감각신경독성(47.1%)이급2도탈발(27.3%).결론 오사리박연합ELF방안치료진전기위암료효학절,불량반응발생솔저,시치득추엄험증적신연합화료방안.
Objective To evaluate the efficacy and safety of the combination of oxaliplatin and ELF (VP16/CF/5-Fu) regimen in the treatment of patients with advanced gastric cancer. Methods Oxaliplatin was given at a dose of 100 mg/m2 i.v. 2 hours D1, calcium folinate (CF) 200 mg/m2 i.v. 1/2 hour D1 - D3, 5-fluorouracil (5-Fu) 500 mg/m2 i.v. 2 hours D1～D3 and etoposide 100 mg/m2 i.v. 3 hours D1～ D3. Cycles were repeated every 21 days. Efficacy and safety were evaluated every 2 cycles. Results Sixty- nine patients were enrolled into the study. All cases were pathologically confirmed as gastric cancer (adenocarcinoma in 57 cases and signet ring cell carcinoma in 12 cases). 42 patients had newly diagnosed disease, and 27 patients had received previous chemotherapy. 62 patients were analyzed for response (7 complete responses and 25 partial responses) with total response rate 51.61%. The median time to progression was 5.7 months and the median overall survival was 9.2 months. The most common hematologic toxicities were anemia (29.0%), leucopenia (51.2%) and thrombocytopenia (21.2%). No grade 4 and grade 5 hematologic toxicities were observed. The most contain non-hematologic toxicities were nausea (46.5%), vomiting (41.1%), peripheral sensory neuropathy (47.1%), and grade 2 alopecia (27.3%) . Conclusion This oxaliplatin combined with ELF regimen shows good efficacy and acceptable safety in advanced gastric cancer patients. It is worthy to be proved as a suitable alternative regimen in this indication.
